Global Drug Designing Tools Market Size is estimated to be valued over US$ 2.7 billion in 2018.

Drug discovery has been at the core of the pharmaceutical companies. Manufacturers spend billions of dollar on R&D to develop innovative and effective drugs. The process is itself not only time consuming but also cost intensive. This is where drug designing tools come in picture. Much of the work has become automated and easier with the advent of computational technology and artificial intelligence. Structure based design has gained wide scale recognition owing to increasing structured data.

Generally, drug designing is carried out either by structural designing or ligand based design. Ligand based design is based on the principle of understanding molecular binding. Whereas structure based designs is based on 3D molecular modeling understanding.

Increasing demand for effective drugs demand across a range of therapeutic applications will drive the demand for drug designing tools worldwide.

Global Drug Designing Tools Market Analysis, By Applications

These tools finds maximum usage in multi databases. It accounted for 33% of global share in 2017.  Predictive analytics will register fastest growth during the forecast period. It will capture a major chunk of the global share by 2028.

Predictive analytics is capable of bridging the gap between drug discovery and outcome and can thus enhance the overall productivity of the pharmaceutical companies. The tool leverages data crunching and algorithms to examine the current state of molecules and thereby offers insightful predictions on the efficacy of drug discovery and expected outcomes. It is rightly a tool that offers competitive advantage to pharma companies.

Global Drug Designing Tools Market Size and Forecast Analysis, by Region

Sales of drug designing tools will be higher in North America followed by Western Europe. North America accounted for over 57% of global share in 2017. The region spends almost 4X higher on R&D compared to global share. And hosts a large number of biotechnology and pharmaceutical companies. As such, it will continue to dominate the global share till 2028.

Global Drug Designing Tools Market Size and Forecast: Competition Landscape

Some key players covered in the report are Biovia Corporation, XtalPi Inc, BioSolveIT GmbH, Agilent Technologies, Schrödinger LLC, ChemAxon, COSMOlogic GmbH & Co., Novo Informatics Pvt. Ltd., OpenEye Scientific Software Inc., Albany Molecular Research Inc.

Product development is at the core of the strategies for these companies. For instance, In 2018, BioSolveIT launched the REAL Space Navigator. Similar such developments are expected to take place during the forecast period.

Drug Designing Tools Market Industry Segmentation

By Functionality:

• Multi Databases
• Virtual Screening
• Model Building Tools
• Predictive Analytics
• Others

By End-use

• Contract Research Organization
• Pharmaceutical companies
• Biotechnology Companies
• Life Science R&D Centers
• Others

By Application

• Molecular Modeling
• Target Prediction
• Docking
• Chemical Screening
• Binding site Prediction
• Other Applications

What Will You Discover in the Report?

• An in-depth analysis of the Drug Designing Tools market across regions – North America, Latin America, Western Europe, Central and Eastern Europe, Asia Pacific, Middle East, and Africa.
• How the Drug Designing Tools market sales is expected to grow throughout the forecast period.
• How geopolitical policies and technological changes will affect the Drug Designing Tools market in near future
• Where the stakeholders should invest to generate higher profit margins
• How consumers (end-users) will reflect to the Drug Designing Tools industry during the forecast period
• Who are the Drug Designing Tools industry leaders and what are the key initiatives taken by them for long term growth

Analyst access with Bekryl Market Analysts

Purchasing of Drug Designing Tools market research report will give clients access to 120 minutes telephonic access with a research analyst. The duration for access to analysts will be based on the report subscription editions.